Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.42 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | VRK2 | Q86Y07 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12496245 | 0.95 | MAPK1 (0.48) | MAPK1KCNH2MAPKAPK2MAP4K4MINK1 | |
| SCHEMBL12077231 | 0.92 | MAPK1 (0.51) | MAPK1KCNH2MAPKAPK2PARP10PARP11 | |
| SCHEMBL18112920 | 0.91 | MAPK1 (0.51) | MAPK1KCNH2MAPKAPK2PARP10PARP11 | |
| SCHEMBL18113049 | 0.91 | MAPK1 (0.50) | MAPK1MAPKAPK2PARP10PARP11GSK3B | |
| SCHEMBL18936953 | 0.90 | MAPK1 (0.42) | MAPK1KCNH2MAPKAPK2PARP10PARP11 | |
| SCHEMBL12078235 | 0.90 | MAPK1 (0.53) | MAPK1MAPKAPK2PARP10PARP11GSK3B | |
| SCHEMBL18113043 | 0.90 | MAPK1 (0.49) | MAPK1KCNH2MAPKAPK2PARP10PARP11 | |
| SCHEMBL12496286 | 0.89 | MAPK1 (0.51) | MAPK1MAPKAPK2PARP10PARP11GSK3B | |
| SCHEMBL18113014 | 0.88 | MAPK1 (0.48) | MAPK1KCNH2MAPKAPK2PARP10PARP11 | |
| SCHEMBL18936979 | 0.88 | KCNH2 (0.46) | MAPK1KCNH2MAP4K4MINK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| EP-2681206-B1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| EP-2681206-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| CN-103429582-A | MST1 kinase inhibitors and method of use thereof | LEXICON PHARMACEUTICALS INC | 2013-12-04 | — | — | CN | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2012121992-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | MAPK1 89/4885KCNH2 4765/4885MAPKAPK2 45/4885 |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK3, STK11 | MAPK1 341/4885KCNH2 2512/4885MAPKAPK2 90/4885 |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | MAPK1 89/4885KCNH2 4765/4885MAPKAPK2 45/4885 |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | STK4, STK3, STK11 | MAPK1 341/4885KCNH2 2512/4885MAPKAPK2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.